<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346122</url>
  </required_header>
  <id_info>
    <org_study_id>CR108376</org_study_id>
    <secondary_id>2017-000229-11</secondary_id>
    <secondary_id>64991524EDI1001</secondary_id>
    <nct_id>NCT03346122</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of JNJ-64991524 compared
      with placebo after administration of single ascending oral doses of JNJ-64991524 (Part 1) and
      multiple ascending oral doses of JNJ-64991524 (Part 2) in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">November 21, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Single Ascending Dose (SAD): Number of Participants with Treatment Emergent Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 20</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment-emergent were events between administration of study drug and up to Day 20 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Multiple Ascending Dose (MAD): Number of Participants with Treatment Emergent Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment-emergent were events between administration of study drug and up to Day 28 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Cardiac Telemetry and Clinically Significant Laboratory Findings</measure>
    <time_frame>Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)</time_frame>
    <description>Number of participants with abnormalities in vital signs, physical examinations, ECG, cardiac telemetry and clinically significant laboratory findings will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of JNJ-64991524</measure>
    <time_frame>Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)</time_frame>
    <description>Plasma concentration assessment will be done to characterize the pharmacokinetics (PK) of JNJ-64991524.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 1</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.</description>
    <arm_group_label>Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 2</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.</description>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 3</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.</description>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 4</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.</description>
    <arm_group_label>Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 5</intervention_name>
    <description>Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.</description>
    <arm_group_label>Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 6</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.</description>
    <arm_group_label>Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.</description>
    <arm_group_label>Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)</arm_group_label>
    <arm_group_label>Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)</arm_group_label>
    <arm_group_label>Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)</arm_group_label>
    <arm_group_label>Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 7</intervention_name>
    <description>Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.</description>
    <arm_group_label>Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 8</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.</description>
    <arm_group_label>Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64991524 Dose Level 9</intervention_name>
    <description>Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.</description>
    <arm_group_label>Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weigh at least 50 kilogram (kg), and have a body mass index (BMI) of 18 kg/ meter
             (m)^2 to 30 kg/m^2, inclusive, at screening

          -  Be otherwise healthy on the basis of physical examination, medical history, vital
             signs, and 12-lead ECG performed at screening and Day-1. This determination must be
             recorded in the participant's source documents and initialed by the investigator

          -  Be otherwise healthy on the basis of clinical laboratory tests performed at screening
             and Day -1. If the results of the serum chemistry panel, including liver enzymes,
             white blood cell count and hematocrit, coagulation, or urinalysis are outside the
             normal reference ranges, the participant may be included only if the investigator
             judges the abnormalities or deviations from normal to be not clinically significant or
             to be appropriate and reasonable for the population under study. This determination
             must be recorded in the participant's source documents and confirmed initialed by the
             investigator

          -  Have the platelet count pretreatment clinical laboratory values not below the normal
             range during Screening and Day -1

          -  A woman must have a negative serum pregnancy test (beta‑human chorionic gonadotropin
             [beta‑hCG]) at screening and a negative urine pregnancy test on Day -2

        Exclusion Criteria:

          -  History of liver or renal insufficiency; significant cardiac, vascular, pulmonary,
             gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or
             metabolic disturbances

          -  Known allergies, hypersensitivity, or intolerance to JNJ-64991524 or its excipients

          -  History of severe allergic reaction, angioedema, or anaphylaxis to drugs or food

          -  Has a history of malignancy before screening. Exceptions are squamous and basal cell
             carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is
             considered cured with minimal risk of recurrence

          -  Has a history of or is infected with human immunodeficiency virus (HIV [positive
             serology for HIV antibody]); tests positive for hepatitis B virus (HBV) infection; has
             antibodies to hepatitis C virus (HCV) at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108376</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

